Amgen Ponders Whether To Seek Injunction
Speaking at a Merrill Lynch conference, Amgen CEO Kevin Sharer acknowledged that a preliminary injunction would stop Roche from immediately launching its Mircera anemia drug. He added, however, that there were two main challenges to procuring an injunction.
“The judge could say, ‘Look, I don’t really want to hear this case twice,’” Sharer...
To view the full article, register now.